Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.

@article{Kim2017CancerderivedEA,
  title={Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.},
  author={Seung Min Kim and Yoosoo Yang and Seung Ja Oh and Yeonsun Hong and Minkoo Seo and Mihue Jang},
  journal={Journal of controlled release : official journal of the Controlled Release Society},
  year={2017},
  volume={266},
  pages={
          8-16
        }
}
An intracellular delivery system for CRISPR/Cas9 is crucial for its application as a therapeutic genome editing technology in a broad range of diseases. Current vehicles carrying CRISPR/Cas9 limit in vivo delivery because of low tolerance and immunogenicity; thus, the in vivo delivery of genome editing remains challenging. Here, we report that cancer-derived exosomes function as natural carriers that can efficiently deliver CRISPR/Cas9 plasmids to cancer. Compared to epithelial cell-derived… CONTINUE READING
11
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis

María Sancho-Albero, Belén Rubio-Ruiz, +5 authors Asier Unciti-Broceta
  • Nature Catalysis
  • 2019

Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma

Malgorzata Czystowska-Kuzmicz, Anna Sosnowska, +20 authors Jakub Golab
  • Nature Communications
  • 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES

In Vivo Delivery Systems for Therapeutic Genome Editing

  • International journal of molecular sciences
  • 2016
VIEW 1 EXCERPT

An update on PARP inhibitors — moving to the adjuvant setting

Y. Li, S. Q. Lv, C. C. Zhang, Y. J. Tian
  • Nat . Rev . Clin . Oncol .
  • 2015

Differential fates of biomolecules delivered to target cells via extracellular vesicles.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2015

E

A. Sonnenblick
  • de Azambuja, H.A. Azim Jr., M. Piccart, An update on PARP inhibitors—moving to the adjuvant setting, Nat. Rev. Clin. Oncol. 12 (1)
  • 2015
VIEW 1 EXCERPT